Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
复制标题
DOI：
10.1158/2159-8290.cd-18-1084
复制
发表时间：
2018-11
期刊：
影响因子：
28.2
通讯作者：
Jeselsohn R
中科院分区：
文献类型：
--
作者：
Schiff R;Jeselsohn R
PALOMA-3临床试验的相关ctDNA研究显示，对氟维司汀和帕博西尼的获得性耐药与RB1、PIK3CA和ESR1的克隆进化和获得性突变有关，其中后两者与氟维司汀耐药有关。这些结果突出了ctDNA作为检测耐药机制和推断下一步治疗方法的工具的潜力。
The correlative ctDNA studies of the PALOMA-3 clinical trial showed that acquired resistance to fulvestrant and palbociclib are associated with clonal evolution and acquired mutations in RB1, PIK3CA, and ESR1, with the latter two related to fulvestrant resistance. These results highlight the potential of ctDNA as a tool to detect mechanisms of resistance and infer the next line of treatment.